<DOC>
	<DOCNO>NCT02253992</DOCNO>
	<brief_summary>The purpose study determine dose Urelumab Nivolumab safe tolerable give together .</brief_summary>
	<brief_title>Study Safety Tolerability Urelumab Administered Combination With Nivolumab Solid Tumors B-cell Non-Hodgkins Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com For Dose Escalation : Subjects previously treat advanced ( metastatic refractory ) solid tumor type Bcell nonHodgkin lymphoma For Cohort Expansion : Subjects must previously treat advanced solid tumor B cell nonHodgkin 's lymphoma eligible Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 For certain subject , willing able provide pretreatment ontreatment fresh tumor biopsy Women childbearing potential men must use acceptable method contraception treatment 23 week treatment woman 31 week men Known central nervous system metastases central nervous system source disease Other concomitant malignancy ( exception per protocol ) Active , know suspected autoimmune disease Uncontrolled significant cardiovascular disease History hepatitis ( B C ) History active latent tuberculosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>